Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HAT1 | O14929 | 2/20 | 0.32 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647035 | 0.88 | MCHR1 (0.37) | ROCK2PLA2G4A | |
| SCHEMBL20647180 | 0.79 | HAT1 (0.38) | ROCK2PLA2G4APDE2AHAT1EP300 | |
| SCHEMBL23889125 | 0.79 | ROCK2 (0.36) | ROCK2PLA2G4APDE2A | |
| SCHEMBL20646896 | 0.79 | HAT1 (0.38) | ROCK2PLA2G4APDE2AHAT1EP300 | |
| SCHEMBL20646800 | 0.79 | ROCK2 (0.33) | ROCK2PDE2APDE10AHAT1EP300 | |
| SCHEMBL17452614 | 0.78 | ROCK2 (0.46) | ROCK2PLA2G4APDE2APDE10AHAT1 | |
| SCHEMBL17321452 | 0.78 | PDE2A (0.39) | ROCK2PDE2AHAT1EP300 | |
| SCHEMBL17452721 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1 | |
| SCHEMBL17321453 | 0.78 | KDM4E (0.48) | KDM4EALDH1A1 | |
| SCHEMBL20647042 | 0.78 | MCHR1 (0.39) | ROCK2KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885PLA2G4A 1543/4885PDE2A 60/4885 |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885PLA2G4A 1538/4885PDE2A 54/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | ROCK2 5/4885PLA2G4A 1538/4885PDE2A 54/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885PLA2G4A 1543/4885PDE2A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.